A prospective, single-arm, phase II study of surufatinib in combination with gemcitabine and nab-paclitaxel for the neoadjuvant treatment of resectable and borderline resectable pancreatic cancer.
Authors: Song Gao, Jihui Hao
Published: 2025-05-28
DOI:
10.1200/jco.2025.43.16_suppl.e16442
Source:
Full article
Abstract
e16442